Carlsmed (CARL) Liabilities and Shareholders Equity (2024 - 2026)

Carlsmed's Liabilities and Shareholders Equity history runs 3 years deep, the most recent figure standing at $118.8 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $118.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $437.0 million (up 743.28% YoY) and the FY2025 annual result came in at $130.1 million, up 151.08% from the prior year.
• Liabilities and Shareholders Equity was $118.8 million for Q1 2026 at Carlsmed, down from $130.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $134.9 million in Q3 2025 and bottomed at $51.8 million in Q4 2024.
• A 3-year average of $97.8 million and a median of $118.8 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 151.08% in 2025, while the deepest fall reached 151.08% in 2025.
• Carlsmed's Liabilities and Shareholders Equity stood at $51.8 million in 2024, then jumped by 151.08% to $130.1 million in 2025, then dropped by 8.72% to $118.8 million in 2026.
• Business Quant data shows CARL's Liabilities and Shareholders Equity at $118.8 million in Q1 2026, $130.1 million in Q4 2025, and $134.9 million in Q3 2025.